Uses
Iptakalim hydrochloride, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist[1].
Biological Activity
Brain blood barrier penetrant ATP-sensitive potassium channel (KATP) opener th at attenuates hypoxia-induced pulmonary arterial hypertension in rats; K(ir) 6.1/SUR2B activator.
Iptakalim hydrochloride is a brain blood barrier penetrant ATP-sensitive potassium channel (KATP) opener th at attenuates hypoxia-induced pulmonary arterial hypertension in rats. Iptakalim hydrochloride is a selective antagonist of α4β2-containing nicotinic acetylcholine receptor (nAChR).
in vivo
Iptakalim (10-60 mg/kg) attenuates nicotine-evoked conditioned responding. Iptakalim also attenuates chamber activity in these nicotine test sessions[3].
.
Iptakalim (60 mg/kg) pretreatment significantly reduced activity (LSD comparisons)[3].
.
| Animal Model: | Thirty male Sprague-Dawley rats weighing 275-299 grams[3]. |
| Dosage: | 0, 10, 30, or 60 mg/kg. |
| Administration: | IP, 10 min before the start of a 4-min test session. |
| Result: | Decreased chamber activity.
Dipper entries following pretreatment with 30 and 60 mg/kg Iptakalim were significantly lower than with 0 (saline) or 10 mg/kg iptakalim pretreatment (Tukey HSD tests).
|
References
[1] Mengyu He, et al. Iptakalim ameliorates hypoxia-impaired human endothelial colony-forming cells proliferation, migration, and angiogenesis via Akt/eNOS pathways. Pulm Circ. 2019 Oct 18;9(3):2045894019875417. DOI:
10.1177/2045894019875417[2] Weiping Xie, et al. Anti-proliferating effect of iptakalim, a novel KATP channel opener, in cultured rabbit pulmonary arterial smooth muscle cells. Eur J Pharmacol. 2005 Mar 28;511(2-3):81-7. DOI:
10.1016/j.ejphar.2005.01.039[3] S Charntikov, et al. Iptakalim attenuates self-administration and acquired goal-tracking behavior controlled by nicotine. Neuropharmacology. 2013 Dec;75:138-44. DOI:
10.1016/j.neuropharm.2013.07.019